Therapy Directory

Abemaciclib clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Abemaciclib as a study intervention. Browse Abemaciclib recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

188

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Hepatocellular Carcinoma
Interventions: Abemaciclib, Nivolumab; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Advanced Cancer, Metastatic Melanoma, Metastatic Non-small Cell Lung Cancer, Colorectal Cancer
Interventions: LY3214996, Midazolam, Abemaciclib, Nab-paclitaxel, Gemcitabine, Encorafenib, Cetuximab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 8
States / cities: Washington D.C., District of Columbia • Sarasota, Florida • Boston, Massachusetts + 4 more

Conditions: Neoplasm Metastasis
Interventions: Drug Cocktail, Abemaciclib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 5
States / cities: Denver, Colorado • Indianapolis, Indiana • Fairway, Kansas + 2 more

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Interventions: Abemaciclib, Trastuzumab Emtansine; Drug · Biological
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: Yuma, Arizona • Jacksonville, Florida • Urbana, Illinois + 3 more

Conditions: Advanced Cancer, Metastatic Cancer, Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, Malignant Mesothelioma, Non-small Cell Lung Cancer
Interventions: LY3023414, Midazolam, Fulvestrant, Pemetrexed, Cisplatin, Abemaciclib, Letrozole; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 6
States / cities: Los Angeles, California • New York, New York • Oklahoma City, Oklahoma + 2 more

Conditions: Metastatic Breast Cancer
Interventions: Ribociclib, Palbociclib, Abemaciclib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 4,320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Metastatic Breast Cancer
Interventions: Ribiciclib, Palbociclib, Abemaciclib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years · Female only
Enrollment: 4,650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Cancer
Interventions: LY3499446, Abemaciclib, Cetuximab, Erlotinib, Docetaxel; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: Indianapolis, Indiana • Middletown, New Jersey • Harrison, New York + 1 more

Conditions: Metastatic Breast Cancer
Interventions: Abemaciclib, Fulvestrant, Standard Chemotherapy; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 55
States / cities: Avondale, Arizona • Phoenix, Arizona • Yuma, Arizona + 51 more

Conditions: Non-Small Cell Lung Cancer Stage IV
Interventions: Abemaciclib, Docetaxel; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 5
States / cities: Fayetteville, Arkansas • Wichita, Kansas • St Louis, Missouri + 2 more

Conditions: Head and Neck Cancer
Interventions: Cohort 1 Not Previously Treated, Cohort 2 Treated Previously; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Breast Cancer, Non-small Cell Lung Cancer, Melanoma, Brain Metastases
Interventions: Abemaciclib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 19
States / cities: Duarte, California • La Jolla, California • San Francisco, California + 15 more

About this Abemaciclib clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Abemaciclib as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Abemaciclib.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Abemaciclib clinical trials

Filter and sort this therapy

Live official records

Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body

T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer

A Study of LY3023414 in Participants With Advanced Cancer

Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors

A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors

A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation

A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer

Abemaciclib and Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer

A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain

About this Abemaciclib clinical trials directory page